Aligning eTMF With the CDISC TMF Reference Model

An eTMF pharma system aligning with the CDISC TMF Reference Model organizes trial documents into the model's standard zones and artifacts — the same taxonomy regulators and CROs already expect — rather than a proprietary folder structure a sponsor has to explain from scratch at every inspection or vendor handoff.

In short: alignment means a system's document structure and metadata map directly onto the TMF Reference Model's 11 zones, so any reviewer — an inspector, a new CRA, a CRO taking over oversight — can find a document by its expected location instead of learning a vendor-specific scheme. That matters more now, not less: the Reference Model is mid-transition to a formal CDISC-governed TMF Standard Model, and a static, one-time mapping risks falling behind.

What Is the CDISC TMF Reference Model?

The TMF Reference Model is a voluntary, industry-developed taxonomy for organizing a Trial Master File — the complete set of essential documents a sponsor must maintain to reconstruct how a clinical trial was conducted. It groups every TMF artifact into 11 standard zones: Trial Management; Central Trial Documents; Regulatory; IRB/IEC and Other Approvals; Site Management; Investigational Product and Trial Supplies; Safety Reporting; Centralized and Local Testing; Third Parties; Data Management; and Statistics.^[1] Within each zone, the model further defines artifacts and sub-artifacts — a specific document type, like a signed protocol or a monitoring visit report — so two sponsors using the model should organize the same kind of document in the same place, regardless of which eTMF system either one runs.

The model originated under the DIA's (Drug Information Association's) Document and Records Management Community in 2010. The TMF Reference Model Group officially affiliated with CDISC in 2022, which has governed the model since — it's now formally known as the CDISC TMF Reference Model. The current version, v3.3.1, was finalized in August 2023 and is the version most eTMF systems in production today are built around.^[2] It has always been a reference, not a regulation — the FDA, EMA, and MHRA have reviewed and commented on it over successive versions, but no agency mandates its use, and it works equally well as an organizing principle for a paper TMF as for a fully electronic one.^[2][3] What makes it valuable in practice isn't legal force; it's that enough of the industry has converged on it that "TMF Reference Model aligned" has become close to table stakes in eTMF RFPs.

Why TMF Reference Model Alignment Matters Right Now

The TMF Reference Model is in the middle of its biggest structural change since it launched. At the CDISC + TMF Interchange conference in late 2025, CDISC — which now formally governs the model through its TMF Reference Model Steering Committee — unveiled TMF Standard Model V1, described as a full transformation of the reference model into a true CDISC Foundational Standard.^[4] The existing v3.3.1 model is slated to be phased out by 2027, with a V4 release positioned as the migration bridge toward the new standard.^[4]

The shift is substantive, not cosmetic. The new standard moves from a loosely-interpreted "model" to a formally versioned "standard" specifically to reduce the inconsistency that's crept in as different vendors and sponsors have interpreted the same zones slightly differently. It introduces a much more granular record-type taxonomy — more than 2,000 distinct record types, compared to the model's current artifact list — and aligns TMF metadata with CDISC's Unified Study Definitions Model (USDM), the same standard increasingly used to describe trial design for downstream systems. A system that treats its current TRM mapping as a one-time configuration, rather than something it can keep current against an evolving standard, is setting up a migration problem for whenever a sponsor's inspection-readiness posture depends on using the version regulators currently expect.

Underneath that transition sits the regulatory logic that hasn't changed: FDA guidance holds that "if it was born electronic it needs to stay electronic," and EMA guidance requires a "fit for purpose system where all changes can be documented and traced." Without a defensible, standard-aligned structure, a sponsor can't demonstrate the unbroken chain of custody either expects.^[3] ICH E6(R3), the most recent revision of Good Clinical Practice guidance, reinforces the same expectation with a stronger emphasis on risk-based, systematic essential-document management rather than a document-by-document checklist approach — another reason a rigid, hard-coded folder structure is a weaker foundation than one built to flex with the standard underneath it.

There's also a practical, day-to-day stake that has nothing to do with the standard's own version number. Sponsors change CROs, bring TMF oversight in-house, or add a new CRO partner mid-study far more often than any one system vendor's roadmap changes — see Kivo's own breakdown of what a TMF storage and migration process actually involves when that handoff happens. Every one of those transitions is faster and lower-risk when both parties are already organizing documents against the same standard zones, instead of one side having to reverse-engineer the other's custom taxonomy before the transfer can even start.

What It Actually Takes for an eTMF System to Align

Genuine TMF Reference Model alignment is more than labeling a few folders with zone names. It requires six things working together:

Native zone-and-artifact structure, not a bolt-on label

Documents should be classified by zone and artifact as native metadata the system understands and can report on — not a folder name a user has to remember to apply consistently. That distinction matters most at scale: with native classification, a sponsor can query "show every artifact in the Regulatory zone across all active sites" directly; with folder-name conventions alone, that query depends on nobody having ever mis-filed a document.

Metadata that supports completeness reporting by zone

Real-time visibility into which zones and artifacts are complete, missing, or overdue — not just a document count — is what makes the model useful day-to-day rather than just at audit time. A system should be able to show a TMF owner exactly which artifact is missing in which zone, for which site, without a manual review.

An audit trail that survives reclassification and migration

As the model itself evolves — v3.3.1 to V4 to the full Standard Model — any remapping of zones or artifacts needs to preserve the existing audit trail rather than resetting it. A migration that updates a document's zone classification but loses the history of who classified it originally and when creates exactly the kind of gap an inspector looks for.

Configurability without losing the standard mapping

Sponsors legitimately need to adapt the model to therapeutic-area or program-specific needs — the model itself is meant to be tailored, not applied rigidly. A system needs to support that configuration while keeping the underlying standard zone/artifact mapping intact, so customization doesn't quietly turn into incompatibility with the next version of the model.

Inspection-ready navigation built on the same structure

The entire value of standardization collapses if an inspector or auditor still has to be walked through a sponsor-specific view. A TMF built on native zone structure should let any reviewer — internal or external — navigate by the standard taxonomy directly, cutting the time it takes to locate a specific artifact during a live inspection.

Portfolio-level reporting, not just per-study tracking

A sponsor running more than one active study needs to see completeness by zone across the whole portfolio, not reconstruct it study by study. That's the same underlying capability Kivo's own eTMF module uses for real-time TMF completeness tracking — zone-level metadata that rolls up cleanly across concurrent studies is what makes a multi-study portfolio view possible without a manual reconciliation exercise every time someone asks for a status update.

What Happens When an eTMF Doesn't Genuinely Align

The gap between a system that labels folders with zone names and one that's genuinely built on the model tends to surface at the worst possible moment — during an inspection, a CRO transition, or a due-diligence review — rather than during day-to-day use. A few failure patterns show up repeatedly:

• The "aligned at setup" trap. A system configured once, at implementation, to match the model's zones can still drift: new document types get filed under whatever folder seems closest, and nothing in the system catches the mismatch because the classification was never native metadata to begin with.
• Reconciliation at CRO handoff. When a TMF built on one vendor's loose interpretation of the model moves to a sponsor's own system (or a new CRO's), someone has to manually map one structure onto the other — exactly the kind of manual step that introduces errors and burns weeks a study timeline doesn't have.
• Version drift going unnoticed. A system built against an older version of the model (or a sponsor-customized variant that quietly diverged from any version) can look compliant internally while falling out of step with what a CRO partner, auditor, or newly-hired regulatory hire expects to see, since "TMF Reference Model aligned" has come to imply a specific, recognizable structure.
• Inspection prep that takes days instead of minutes. If finding a specific artifact requires asking someone who remembers where it was filed, rather than navigating the standard zone structure directly, inspection readiness depends on institutional memory — precisely the single point of failure a standardized taxonomy is supposed to remove.

Evaluation Criteria for TMF Reference Model Alignment

When evaluating whether an eTMF platform genuinely aligns with the TMF Reference Model — rather than just mentioning it in marketing copy — a few direct questions separate real alignment from a label:

• Is zone/artifact classification native metadata, or a folder-naming convention? Ask to see a completeness report generated directly from that metadata, not a manually-maintained tracker.
• Which model version is the system built on, and what's the vendor's plan for V4 and the TMF Standard Model? A vendor with no stated migration path is asking sponsors to absorb that risk themselves later.
• Does the system support configuring zones/artifacts for a specific program without breaking the standard mapping? Ask for a concrete example of a therapeutic-area-specific customization that was made without losing TRM compatibility.
• Can completeness and audit-trail history be queried across the whole TMF, not just within one study? Portfolio-level completeness reporting by zone is a meaningfully different capability than per-study document counts.
• Does the audit trail survive a reclassification or migration event? This is worth asking as a direct, specific question during a demo rather than assuming it from a general audit-trail claim.

How the Leading eTMF Platforms Compare

The table below compares how publicly-available information describes each platform's approach to TMF Reference Model alignment. This is a structural comparison, not an independent ranking or endorsement — Kivo is included as one option among the set, evaluated on the same basis as the others, and sponsors should confirm current capabilities directly with each vendor before deciding.

Platform-by-Platform: Alignment in Practice

Each profile below follows the same shape — overview, capabilities, strengths, what to watch for, and ideal use cases — so no platform, including Kivo, gets a longer or more favorable write-up than another.

Veeva Vault eTMF

Overview: Veeva Vault eTMF is part of Veeva's broader Vault Clinical suite, one of the most widely deployed eTMF platforms among large and mid-size sponsors and CROs.

Capabilities: Document and zone/artifact classification aligned to the TMF Reference Model, integrated with Veeva's wider clinical operations and submission tooling.

Strengths: Broad ecosystem integration for organizations already standardized on multiple Veeva Vault applications; established presence across large-scale, multi-study clinical programs.

Watch for: As with most enterprise-suite platforms, implementation and validation timelines and total cost of ownership tend to scale with the breadth of the Vault ecosystem a sponsor adopts — worth scoping carefully against a program's actual size.

Ideal use cases: Larger, enterprise-scale sponsors and CROs already running other Veeva Vault applications who want eTMF on the same platform.

Montrium

Overview: Montrium offers a dedicated eTMF and quality-document management platform with a long-standing focus on TMF Reference Model alignment specifically.

Capabilities: TRM-aligned zone/artifact structure with document and quality-management workflows built around clinical trial compliance.

Strengths: Deep, long-running familiarity with the Reference Model's own evolution, reflected in the vendor's public commentary tracking changes like the shift toward the CDISC TMF Standard Model.

Watch for: As a narrower-scope vendor than a full unified-platform competitor, sponsors needing RIM or broader quality management beyond eTMF may need to evaluate a separate system or integration.

Ideal use cases: Sponsors prioritizing a dedicated, TRM-focused eTMF vendor over a broader compliance suite.

Florence eBinders

Overview: Florence eBinders is an eTMF platform with particular strength on the site- and CRA-facing side of trial document management.

Capabilities: TRM-aligned document structure with workflows oriented around site coordinators and CRA document collection and review.

Strengths: Strong adoption among investigator sites specifically, which can smooth document collection directly at the source.

Watch for: Sponsor-side, portfolio-level oversight capabilities and broader compliance-suite functionality (RIM, QMS) are not this platform's core focus.

Ideal use cases: Sponsors and CROs where site- and CRA-facing document workflows are the primary pain point.

IQVIA eTMF

Overview: IQVIA eTMF is offered as part of IQVIA's broader clinical trial technology and CRO services portfolio.

Capabilities: TRM-aligned eTMF functionality integrated with IQVIA's wider clinical operations and data services.

Strengths: Natural fit for sponsors already using IQVIA as a CRO, with the potential for closer operational alignment between the TMF and the broader trial-execution relationship.

Watch for: Sponsors not otherwise working with IQVIA may find a standalone, CRO-agnostic eTMF a simpler evaluation.

Ideal use cases: Sponsors already contracting with IQVIA for CRO services who want eTMF on the same vendor relationship.

Ennov

Overview: Ennov offers a modular document and compliance management suite spanning eTMF, RIM, and QMS.

Capabilities: TRM-aligned eTMF document management as one module within a configurable, multi-module compliance platform.

Strengths: Configurability across modules for organizations wanting to tailor workflows across eTMF, regulatory, and quality functions under one vendor.

Watch for: Breadth of configuration options can mean a longer initial setup and validation process compared with a more narrowly-scoped or pre-configured system.

Ideal use cases: Organizations wanting a configurable, modular suite across eTMF, RIM, and QMS from a single vendor.

Kivo

Overview: Kivo's eTMF module is built natively on the TMF Reference Model's 11 zones, as one of four activatable areas (alongside DMS, RIM, and QMS) sharing a single Part 11-compliant document core.

Capabilities: Zone- and artifact-level metadata drives real-time, portfolio-level completeness reporting rather than per-study manual tracking; inspector-specific access can be granted in minutes, showing only finalized document versions, navigable by the same standard zone structure an inspector already expects; TMF migration tooling ingests documents, metadata, and audit trails from prior systems — including recompiling a single unified audit trail across documents that passed through multiple previous platforms — via a validated process (Elevar Therapeutics migrated 19 TMF studies, 73,794 documents, in 72 days using this process).

Strengths: Zone/artifact structure isn't a standalone eTMF feature — it shares the same document core, audit trail, and e-signature as Kivo's RIM and QMS modules, so a sponsor evaluating eTMF alongside other compliance needs isn't managing a separate integration. Every release ships with CSA-aligned validation evidence that customers review rather than re-performing themselves.

Watch for: As with any platform built for clinical-stage biotech specifically, sponsors running very large, multi-thousand-site global programs should evaluate scale requirements directly against Kivo's current customer base (200+ sponsor, consultant, and CRO teams) rather than assuming parity with the largest enterprise suites.

Ideal use cases: Clinical-stage biotech sponsors and the CROs/consultancies supporting them who want eTMF, DMS, RIM, and QMS unified on one validated, TRM-aligned document core rather than stitched together from separate systems.

How to Choose

The right platform depends less on which vendor says "TMF Reference Model aligned" — nearly every credible eTMF system in this category does — and more on three practical questions: how that alignment is implemented (native metadata versus folder convention), whether the vendor has a stated plan for the model's move toward the CDISC TMF Standard Model, and whether eTMF needs to sit alongside RIM and QMS on the same document core or can stand alone.

A sponsor running eTMF as a single, isolated system has a meaningfully different evaluation than one looking to unify eTMF with regulatory submissions and quality management under one validated platform. The first group should weight vendor specialization and depth within eTMF specifically — a dedicated, long-running eTMF vendor's familiarity with the model's own history can be a genuine advantage. The second group should weight how cleanly zone/artifact metadata, audit trail, and permissioning carry across modules, since the value of unification erodes quickly if eTMF's TRM alignment lives in a different data model than RIM's submission tracking or QMS's audit management.

Team size and growth trajectory matter too. A sponsor already running multiple concurrent studies, or expecting to activate RIM or QMS within the next year or two, is generally better served evaluating a platform's full module roadmap now rather than treating eTMF as a standalone purchase and re-evaluating everything later. Conversely, a sponsor with a narrow, single-study need and no near-term plans to expand scope may reasonably prioritize a specialized point solution over a broader platform.

Whichever direction a sponsor leans, confirming the specific alignment mechanics directly with each vendor — rather than taking "TRM aligned" as a settled checkbox — is worth the extra diligence given how much the standard itself is changing over the next two years. A short, specific list of questions (see the evaluation criteria above) during a vendor demo will surface the difference between a system built around the model and one that's merely labeled to match it, far more reliably than a feature-sheet comparison alone.

FAQ

Which eTMF system simplifies CRO-sponsor collaboration?

The eTMF systems that simplify CRO-sponsor collaboration best are the ones giving both parties real-time, permissioned access to the same TMF Reference Model-aligned structure, rather than each side maintaining a separate copy that has to be reconciled. Role-based access lets a sponsor retain oversight of a CRO-managed TMF without losing visibility into completeness or audit history.

Clinical document management focused on GCP audit readiness — what does that actually require?

GCP audit readiness requires a document structure an auditor can navigate using standard terminology (the TMF Reference Model's zones), a complete and uneditable audit trail, and the ability to show only finalized, non-draft versions to an inspector within minutes rather than days of advance preparation.

What TMF storage options work best for high-volume clinical documents?

At high document volumes, fast metadata-driven retrieval — by zone, artifact, site, or document type — matters more than raw storage capacity. Per-GB pricing models become significantly more expensive at scale than a flat or included-storage structure, and search needs to stay fast as document counts climb into the tens of thousands.

Does the TMF Reference Model apply to paper TMFs, or only electronic ones?

Both. The model is a voluntary, technology-agnostic taxonomy — it defines how TMF content should be organized by zone and artifact regardless of whether the underlying TMF is paper, electronic, or a hybrid of the two, and regulators have reviewed it under that same technology-neutral framing.

Will my current TMF Reference Model-aligned eTMF still be compliant once the CDISC TMF Standard Model is finalized?

Likely not without a migration step. TMF Standard Model V1 and its V4 bridge introduce more granular record types and USDM metadata alignment that today's v3.3.1 model doesn't define. The practical question for a vendor now is whether that migration is a stated roadmap item, or something a sponsor manages alone once v3.3.1 phases out around 2027.

Sources

1. Kivo's eTMF documentation and the TMF Reference Model Steering Committee's published zone structure — 11 zones as adopted across current TRM-aligned eTMF systems.
2. TMF Reference Model Steering Committee / CDISC, version history through v3.3.1 (August 2023); originated under the DIA's (Drug Information Association's) Document and Records Management Community in 2010, with the TMF Reference Model Group officially affiliating with CDISC in 2022.
3. U.S. Food and Drug Administration and European Medicines Agency guidance on computerized systems and electronic trial master files — "born electronic" record-retention principle and "fit for purpose" system requirement.
4. CDISC + TMF Interchange conference (2025) announcement of TMF Standard Model V1; current TRM v3.3.1 targeted for phase-out by 2027, with V4 as a migration bridge; metadata alignment with CDISC's Unified Study Definitions Model (USDM) and expansion to 2,000+ granular record types.